other material
confidence high
sentiment positive
materiality 0.90
NeOnc NEO100 Phase 2a meets primary endpoint: PFS-6 48.9% vs 20% benchmark
NEONC TECHNOLOGIES HOLDINGS, INC.
- PFS-6 48.9% (95% CI 26.3-68.1) vs 20% SOC benchmark, p=0.0047; median PFS 3.91 mo.
- Median OS 26.09 months; OS rates 86.7% at 6 mo, 60.9% at 12 mo, 54.1% at 24 mo.
- 5 of 24 patients remain on treatment; one progression-free ~19 mo, one partial response 114 days; ORR 8.3%.
- No major toxicities; adverse events predominantly low-grade; self-administered intranasally at home.
- Company to request Type B FDA meeting to align on registrational path; full data at future medical meeting.